Recent news

2-6 June 2024

CuraVac team will be pleased to welcome you the Belgian Booth at Bio San Diego 2024.

14-16 May 2023

CuraVac presented its new development to potential investors at BioEquity 2023 in Dublin.

6 October 2021

CuraVac was honored to participate in the International Symposium on the Treatment of Brain and Neurology Disorders held in Taipei, Taiwan. Among other expert speakers from Asia, Taiwan and Europe, Dr. Stéphane Huberty M.D., gave a keynote presentation on the new research and current development of CuraVac’s Therapeutic Vaccines.

https://accessus.cloud/IEK/20211005/eDM_en.html

1 June 2018

WE ARE PLEASED TO ANNOUNCE THAT THE RESULTS OF THE PHASE 1B OF OUR TARGETED ACTIVE THERAPY DEMONSTRATES AN EXCELLENT SAFETY PROFILE.

19 June 2017

We are pleased to annouce the approval of Phase 2 of our Active Targeted Immunotherapy for Myasthenia Gravis by the UZA Ethics Committee on the 19th of June 2017, and the Belgian and Dutch Regulatory Authorities (May 2017).

19 – 22 June 2017

Thank you for visiting us at Bio 2017 in San Diego on the Belgian Booth and/or meeting us thru One-on-One Partnering.

15 – 17 MAY 2017

THE PRELIMINARY RESULTS OF THE ONGOING PHASE 1B CLINICAL TRIAL ON PATIENTS OF CV-MG01 VS. PLACEBO DEMONSTRATES SAFETY AND INDICATES EFFICACY AS COMMUNICATED AT THE 13TH INTERNATIONAL CONFERENCE ON MYASTHENIA GRAVIS AND RELATED DISORDERS AT THE NEW YORK ACADEMY OF SCIENCE ON THE 16TH OF MAY 2017.

7 – 9 November 2016

Thank you vor visiting us at Bio Europe 2016 in Köln.

5 – 9 June 2016

Thank you for visiting us at Bio 2016 in San Francisco.

November 2015

THE PHASE 1B OF CURAVAC’S MG TARGETD ACTIVE THERAPY STARTED AT THE ANTWERP UNIVERSITY HOSPITAL IN BELGIUM.

2 – 4 November 2015

Thank you for meeting us at Bio Europe 2015 in Munich.

October 2015

CuraVac’s MG Targeted Active Therapy receives Clinical Trial Authorization (CTA) in Belgium and the Ethical Committee of the University Hospital of Antwerp (UZA) gives its authorization for a Phase 1b trial on 24 to 32 patients.

15 – 19 June 2015

Thank you for meeting us at Bio 2015 in Philadelphia.

10 December 2014

CURAVAC WON THE BEST PRESENTATION AWARD AT THE EUROPEAN VENTURE CONTEST 2014 (December 2014)

3 – 5 November 2014

Thank you for meeting us at Bio Europe 2014 in Frankfurt.

9 October 2014

CURAVAC WON THE BEST PRESENTATION AWARD AT THE LIFE SCIENCES INVESTMENT FORUM (October 2014).

23 – 26 June 2014

Thank you for visiting us at Bio 2014 in San Diego on the Belgian Pavilion.

6 June 2014

CURAVAC AND THE MYASTERIX PROJECT WON THE AWARD OF THE BEST IMMUNOTHERAPIES & VACCINES PROJECT AT BIOVISION 2014 (June 2014)

June 2014

CuraVac will present the company and the myasterix project at BioVision on June 6th in Lyon, France.

April 2014

CuraVac was present at Buzz4Bio.

October 2013

CuraVac is proud to announce the start of the Myasterix project.

April 2013

An independent Jury deems the Myasterix project one of the seven best immunotherapeutic projects and recommends that the European Commission subsidizes the project.

April 2013

CuraVac attends the Bio 2013 convention in Chicago.

October 2012

CuraVac creates the Myasterix consortium.

June 2012

CuraVac attends the Bio 2012 convention in Boston.